Core Viewpoint - Chronic pain is a significant public health challenge, with over 300 million patients in China, and the market for innovative pain management solutions is rapidly evolving due to increasing demand for effective treatments and the introduction of new technologies [2][16]. Group 1: Company Overview - Beijing Xinyun Medical Technology Co., Ltd. focuses on comprehensive solutions for chronic pain, utilizing technologies in neurostimulation, minimally invasive intervention, and transcutaneous electrical stimulation [3]. - The company aims to provide personalized treatment plans for various types of pain, including postherpetic neuralgia, chronic low back pain, and diabetic neuropathy [3]. Group 2: Market Dynamics - Chronic pain has been recognized by WHO as an independent chronic disease, affecting over 20% of adults globally, with a significant increase in pain-related hospitalizations in China [2]. - The demand for new treatment options is growing, driven by the limitations of traditional drug therapies, which have an efficacy rate of less than 50% for certain pain types [2]. Group 3: Product Innovations - New Xinyun Medical has developed the AI-closed-loop spinal cord stimulation (SCS) system, NewStim®, which can automatically adjust stimulation parameters based on real-time monitoring, addressing the limitations of existing open-loop systems [7][5]. - The company also introduced NewMild®, a minimally invasive device for treating lumbar spinal stenosis, which offers advantages such as reduced trauma and faster recovery compared to traditional surgery [8][10]. Group 4: Strategic Initiatives - The recent B+ round of financing will support the registration and clinical trials of core products, international expansion, and the enhancement of AI algorithms and material research capabilities [15]. - The company is exploring a comprehensive pain management model that integrates products, services, and data, aiming to improve patient education and acceptance of new treatment technologies [11][15]. Group 5: Future Outlook - With national policies promoting pain management and the increasing recognition of smart medical devices, the next 2-3 years are expected to be critical for the company to scale its products and establish its brand [15][16].